Long-term Safety and Efficacy of Indacaterol, a Long-Acting β2-Agonist, in Subjects With COPD
نویسنده
چکیده
a From the Asthma and Airway Centre, University Health Network, Toronto Western Hospital, Toronto, ON, Canada b Department of Medicine, University of Toronto, Toronto, ON, Canada c Department of Pulmonary Critical Care, Allergy and Sleep Medicine, University of Nebraska Medical Center, Omaha, NE d Novartis Horsham Research Centre, Horsham, West Sussex, England e Novartis Pharmaceuticals, East Hanover, NJ
منابع مشابه
Efficacy and safety of conventional long acting β2- agonists: systematic review and meta-analysis
Background: Chronic obstructive pulmonary disease (COPD) is usually considered one of the leading causes of death worldwide, so finding proper therapeutic strategies for this disease is of high importance. In this meta-analysis, we reviewed the existing literature on the efficacy and safety of conventional long acting beta agonists (LABAs) in COPD patients. Methods: We searched MEDLINE and G...
متن کاملComparative efficacy of indacaterol in chronic obstructive pulmonary disease
Long-acting bronchodilators have been shown to improve multiple clinical outcomes in chronic obstructive pulmonary disease (COPD) including lung function, symptoms, dyspnea, quality of life, and exacerbations. Indacaterol is a novel, inhaled, long-acting β2-agonist providing 24-hour bronchodilation with once-daily dosing. It is currently approved for the maintenance treatment of COPD to be admi...
متن کاملRole of indacaterol and the newer very long-acting β2-agonists in patients with stable COPD: a review
Bronchodilators are central drugs in the management of patients with chronic obstructive pulmonary disease (COPD). Indacaterol was the first agent of the novel family of very long-acting β2-agonists to be used as an inhaled bronchodilator for COPD and provides 24-hour therapeutic action, thus allowing once-daily administration. Data from clinical trials show that indacaterol has a bronchodilato...
متن کاملThe safety of long-acting β2-agonists in the treatment of stable chronic obstructive pulmonary disease
BACKGROUND Inhaled long-acting bronchodilators are the mainstay of pharmacotherapy for chronic obstructive pulmonary disease (COPD). Both the twice-daily long-acting β(2)-adrenoceptor agonists (LABAs) salmeterol and formoterol and the once-daily LABA indacaterol are indicated for use in COPD. This review examines current evidence for the safety of LABAs in COPD, focusing on their effect on exac...
متن کاملNew developments in the management of COPD: clinical utility of indacaterol 75 μg
Chronic obstructive pulmonary disease (COPD) is a global health challenge and a major cause of mortality worldwide. Bronchodilators, particularly long-acting β2-agonists and long-acting antimuscarinic agents, used singly or in combination, aim to improve lung function, reduce symptoms, prevent exacerbations, and enhance quality of life of COPD patients. Indacaterol is a novel, inhaled, long-act...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2006